Pediatric Acute Kidney Injury in COVID-19

NCT ID: NCT04466306

Last Updated: 2021-12-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-04-15

Study Completion Date

2021-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is an observational registry of children with or suspected to have SARS CoV2 (COVID-19) admitted to pediatric intensive care units (PICU). This registry will help describe the prevalence, rate and severity of acute kidney injury (AKI) in children with Severe Acute Respiratory Syndrome Coronavirus-2(SARS CoV2) across the world. The registry will be developed using a point prevalence methodology and then full retrospective review. Once a week, from April through June 2020, data collection will occur in "real-time" to estimate a weekly point prevalence of AKI and renal replacement therapy (RRT). The operational definition of "patients under investigation" (PUIs) will be used to identify the denominator of patients to be studied. The PUIs will be cohorted into SARS CoV2 test positive, test negative, test pending, or test unavailable. The primary aim of this study is to deliver a global, objective data driven analysis of the burden of AKI in virus positive patients or patients under investigation (PUI) who are admitted to the pediatric intensive care unit.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary purpose of the data collection will be to provide a descriptive analysis of the burden and characteristics of AKI in children with SARS-CoV2 proven or suspected infection across the world. This is a prospective, point prevalence study. Data collection will occur once a week during the months of April through June 2020.

The protocol for the point prevalence is for each individual participating site to conduct a surveillance study on predetermined dates of their intensive care units (pediatric medical, surgical, cardiac ICUs) for patients by the inclusion and exclusion criteria. The study is strictly observational. Data will only be captured on the predetermined dates listed. The dates have been chosen to reflect the estimated surge and peak of the virus spread in North America, Europe, Africa, Asia, and Australia. The rationale for performing an urgent point prevalence estimation study first, includes the following: a) there is almost no knowledge on AKI rate, severity of AKI or how current pandemic-setting AKI phenotype differs from what we know of AKI in children prior to the pandemic. A rapidly-performed, high feasibility-designed point prevalence estimation study, with minimal data collection will provide rapid, almost instantaneous dissemination of results to the international community. Based on the results of this study, a follow-up study is planned for a full retrospective data collection of all viral positive patients. Understanding the burden of pediatric AKI during this pandemic within the current context of acute health burden in the healthcare settings and enable planning and feasibility evaluation for quality of care measures and potentially for upcoming technology needs and/or sharing of RRT technology with adult care units; b) an urgent point-prevalence estimation study with minimal but key data collection will inform on any changes to design, sample size requirements or data points for the larger granular longitudinal retrospective study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Kidney Injury COVID

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient less than or equal to 25 years of age
* Receiving clinical care in the pediatric intensive care unit (PICU) on a study day in April - June 2020
* Patient considered a "Person Under Investigation" and/or tested positive for SARS-CoV2 (COVID-19)

Exclusion Criteria

• None
Minimum Eligible Age

7 Days

Maximum Eligible Age

25 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Children's Hospital Medical Center, Cincinnati

OTHER

Sponsor Role collaborator

Children's of Alabama

OTHER

Sponsor Role collaborator

The Hospital for Sick Children

OTHER

Sponsor Role collaborator

Children's Healthcare of Atlanta

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Rajit K Basu, MD

Role: PRINCIPAL_INVESTIGATOR

Children's Healthcare of Atlanta

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Children's Hospital of Alabama

Birmingham, Alabama, United States

Site Status

Arkansas Children's Research Institute

Little Rock, Arkansas, United States

Site Status

Cedars-Sinai Maxine Dunitz Children's Health Center

Los Angeles, California, United States

Site Status

UCLA Mattel Children's Hospital

Los Angeles, California, United States

Site Status

Lucile Packard Children's Hospital Standford

Palo Alto, California, United States

Site Status

Rady Children's Hospital San Diego

San Diego, California, United States

Site Status

Children's Hospital Colorado

Aurora, Colorado, United States

Site Status

Yale New Haven Children's Hospital

New Haven, Connecticut, United States

Site Status

UF Health Shands Children's Hospital

Gainesville, Florida, United States

Site Status

Children's Healthcare of Atlanta

Atlanta, Georgia, United States

Site Status

Comer Children's Hospital - UChicago Medicine

Chicago, Illinois, United States

Site Status

Riley Hospital for Children

Indianapolis, Indiana, United States

Site Status

University of Iowa Stead Family Children's Hospital

Iowa City, Iowa, United States

Site Status

Children's Mercy

Kansas City, Kansas, United States

Site Status

John Hopkins Children's Center

Baltimore, Maryland, United States

Site Status

Boston Children's Hospital

Boston, Massachusetts, United States

Site Status

C.S. Mott Children's Hospital

Ann Arbor, Michigan, United States

Site Status

Helen DeVos Children's Hospital

Grand Rapids, Michigan, United States

Site Status

Beaumont Children's Hospital

Royal Oak, Michigan, United States

Site Status

St. Louis Children's Hospital of Washington University

St Louis, Missouri, United States

Site Status

Oishei Children's Hospital of Buffalo

Buffalo, New York, United States

Site Status

Golisano Children's Hospital - University of Rochester Medicine

Rochester, New York, United States

Site Status

Stony Brook Children's Hospital

Stony Brook, New York, United States

Site Status

Levine Children's Hospital

Charlotte, North Carolina, United States

Site Status

Duke Children's Hospital and Health Center

Durham, North Carolina, United States

Site Status

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States

Site Status

Nationwide Children's Hospital

Columbus, Ohio, United States

Site Status

Penn State Children's Hospital

Hershey, Pennsylvania, United States

Site Status

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

Site Status

UPMC Children's Hospital of Pittsburgh

Pittsburgh, Pennsylvania, United States

Site Status

Lifespan Hasbro Children's Hospital

Providence, Rhode Island, United States

Site Status

Medical University of South Carolina Shawn Jenkins Children's Hospital

Charleston, South Carolina, United States

Site Status

Seattle Children's Hospital

Seattle, Washington, United States

Site Status

Stollery Children's Hospital

Edmonton, Alberta, Canada

Site Status

McMaster Children's Hospital

Hamilton, Ontario, Canada

Site Status

The Hospital for Sick Children (SickKids)

Toronto, Ontario, Canada

Site Status

Soroka University Medical Center

Beersheba, , Israel

Site Status

Dana-Dwek Children's Hospital

Tel Aviv, , Israel

Site Status

Shizuoka Children's Hospital

Shizuoka, , Japan

Site Status

Institute for Mother and Child Healthcare

Belgrade, , Serbia

Site Status

University Children's Hospital

Belgrade, , Serbia

Site Status

Hospital 12 de Octubre

Madrid, , Spain

Site Status

Birmingham Children's Hospital NHS

Birmingham, , United Kingdom

Site Status

Alder Hey Children's Hospital NHS

Liverpool, , United Kingdom

Site Status

King's College Hospital NHS

London, , United Kingdom

Site Status

St. George's University Hospital NHS

London, , United Kingdom

Site Status

Great Ormond Street Hospital NHS

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada Israel Japan Serbia Spain United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ChildrensHA

Identifier Type: -

Identifier Source: org_study_id